Details

NameSymbolSector
LASA SUPERGENERICS LIMITEDLASAPharmaceuticals
Open
10
High
10
Low
9.61
Close
9.75
Volume
40936
Exchange
nse
Time
14/08

Outlook

Score:  

0

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Lasa Supergenerics is  
None
Estimated Stoploss of Lasa Supergenerics is ₹  
10
Lasa Supergenerics has a  
Bearishℹ
 pattern. 
Formation of  
None
 candle pattern indicates the trend direction of Lasa Supergenerics is  
Unpredictableℹ
. 

Trend

Lasa Supergenerics is in  
Strong Downtrendℹ
. 
Price of Lasa Supergenerics is  
Downℹ
 by  

12.08

%. 
Target
Buy @ 

9.5

Sell @ 

10.49

Volume

The trade volumes of Lasa Supergenerics have become  
Deficientℹ
The volume trend for Lasa Supergenerics is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Lasa Supergenerics is  

Down

 by  

73.23

% 

Valuation

The current market price of Lasa Supergenerics is  
Undervaluedℹ

Financials

Balance
The balance sheet of Lasa Supergenerics is:  

Balanced

Cashflow
Lasa Supergenerics has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2025)

13.33% i.e. ₹ 2cr spent in operatingℹ
53.33% i.e. ₹ 8cr earned in investingℹ
33.33% i.e. ₹ 5cr spent in financingℹ
0% in otherℹ
Lasa Supergenerics has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Upℹ
 by  

100

%. 

(*Mar 2024)

66.67% i.e. ₹ 2cr earned in operatingℹ
0% in investingℹ
33.33% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Income
The income of Lasa Supergenerics is  

₹ 20cr

 and  

Loss

 is :  

₹ 21cr

(*Jun 2025)

Lasa Supergenerics Losses increased by:  

50

% and Income is Down by:  

51.22

% 

(*Jun 2025)

The income of Lasa Supergenerics is  

₹ 41cr

 and  

Loss

 is :  

₹ 14cr

(*Mar 2025)

Lasa Supergenerics Losses increased by:  

380

% and Income is Up by:  

24.24

% 

(*Mar 2025)

The income of Lasa Supergenerics is  

₹ 33cr

 and  

Profit

 is :  

₹ 5cr

(*Dec 2024)

Lasa Supergenerics Profit is up by:  

266.67

% and Income is Down by:  

19.51

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.